Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Merck Sharp & Dohme LLC
MediLink Therapeutics (Suzhou) Co., Ltd.
BioNTech SE
CSPC Megalith Biopharmaceutical Co.,Ltd.
Canadian Cancer Trials Group
Gilead Sciences
AstraZeneca
Wake Forest University Health Sciences
ALX Oncology Inc.
Fudan University
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Hoosier Cancer Research Network
Sun Yat-sen University
Emory University
Sun Yat-sen University
Sichuan Baili Pharmaceutical Co., Ltd.
Hoffmann-La Roche
Incyte Corporation
Daiichi Sankyo
Sanofi
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Japan Breast Cancer Research Group
Eli Lilly and Company
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Fox Chase Cancer Center
University of Virginia
Eli Lilly and Company
Sichuan Baili Pharmaceutical Co., Ltd.
Sun Yat-sen University
Mayo Clinic
University of California, San Francisco
Cantargia AB
West German Study Group
UNICANCER
Cyteir Therapeutics, Inc.
Shanghai Yizhong Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
Guangdong Provincial People's Hospital
Eli Lilly and Company
Actuate Therapeutics Inc.
Novartis
Cantargia AB
G1 Therapeutics, Inc.